Matinas BioPharma Announces Positive Data in the Ongoing EnACT Trial of MAT2203 (Oral Amphotericin B) for the Treatment of Cryptococcal Meningitis, Exceeding the Prespecified Primary Endpoint Threshold

NEXT STORY
TCR2 Therapeutics to Announce Extended Results from Ongoing Phase 1/2 Trial of Gavo-cel in Mesothelin-Expressing Solid Tumors
PREV STORY
The Worldwide Endoscopy Visualization Systems Industry is Expected to Reach $35 Billion by 2028
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Coherus BioSciences Completes Patent Dance Exchange with Amgen for Neulasta Biosimilar

REDWOOD CITY, Calif., April 25, 2017 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), announced ...

author_avatar
NASDAQ Market News

The Global Biologics Market is expected to grow from USD 236,057.71 Million in 2019 to USD 304,866.47 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 4.35%

author_avatar
NASDAQ Market News

Tiziana Announces Publication of a Peer Reviewed Article on Data from the Clinical Trial with Intranasally Administered Foralumab, Its Proprietary Fully Human Anti-CD3 Monoclonal Antibody, in Mild to Moderate COVID-19 Patients in Brazil

author_avatar
NASDAQ Market News